European Multidisciplinary Conference in Thoracic Oncology, Lugano 09

Teaming up to catch the winds of change in thoracic oncology
 
 Teaming up to catch the winds of change in thoracic oncology
 
The European Society for Medical Oncology (ESMO), the European Society for Therapeutic Radiology and Oncology (ESTRO), the European Society of Thoracic Surgeons (ESTS) and the European Respiratory Society (ERS) have identified the need to cooperate in the education of healthcare professionals treating malignant chest tumors.

A regular multidisciplinary, educational meeting on this topic is considered important for strengthening general knowledge and providing an updated overview of prevention, screening, diagnosis, treatment modalities and results of translational research. This Conference facilitates interaction between the specialities in order to promote an integrated approach to diagnosis and treatment of chest tumors and to strengthen European cooperation and scientific exchange in multidisciplinary management of lung cancer.

Official Welcome
1
ESMO
Place a comment or grade

R. Stahel (Zurich, Switzerland)
Webcast
2
City of Lugano
Place a comment or grade

A. Jelmini (Lugano, Switzerland)
Webcast
3
ESMO Scientific Committee
Place a comment or grade

R. Pirker (Vienna, Austria)
Webcast

Keynote lecture
4
Milestones in the management of lung cancer
Place a comment or grade

R. Stahel (Zurich, Switzerland)
Webcast

WHO Keynote lecture
5
A thousand seconds, a thousand lives
Place a comment or grade

B. Zolty (Geneva, Switzerland)
Webcast

Lung cancer biology: Clinical implications
6
New findings in the molecular biology of lung cancer: clinical application
Place a comment or grade

D. Gandara (Sacramento, USA)
Webcast
7
Prognostic factors in non-small cell lung cancer
Place a comment or grade

P. O'Byrne (Dublin, Ireland)
Webcast
8
Predictive factors in NSCLC
Place a comment or grade

E. Felip (Barcelona, Spain)
Webcast
9
Clinical trials based on biomarkers
Place a comment or grade

R. Rosell (Barcelona, Spain)
Webcast

Diagnosis and staging
10
Invasive staging
Place a comment or grade

P. De Leyn (Leuven, Belgium)
Webcast
11
Individualised staging: practical implications
Place a comment or grade

S. Spiro (London, United Kingdom)
Webcast

Prevention and screening
12
The primary prevention of lung cancer
Place a comment or grade

G. Ostoros (Budapest, Hungary)
Webcast
13
Lung cancer screening
Place a comment or grade

R. Van Klaveren (Rotterdam, The Netherlands)
Webcast

NSCLC stage I and II. Treatment standards and new developments
14
Surgery
Place a comment or grade

B. Passlick (Freiburg, Germany)
Webcast
15
Radiotherapy with curative intent for stage I and II non-small cell lung cancer
Place a comment or grade

D. De Ruysscher (Maastricht, The Netherlands)
Webcast
16
Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development
Place a comment or grade

G. Scagliotti (Turin, Italy)
Webcast
17
Follow-up: why and how
Place a comment or grade

V. Westeel (Besancon, France)
Webcast

NSCLC stage III
18
Heterogeneity of stage III and its implication on treatment
Place a comment or grade

R. M. Huber (Munich, Germany)
Webcast
19
Surgery
Place a comment or grade

W. Weder (Zurich, Switzerland)
Webcast
20
New developments in radiotherapy
Place a comment or grade

R. Dziadziuszko (Gdansk, Poland)
Webcast

NSCLC Stage IV. Treatment standards and new developments
21
First-line therapy
Place a comment or grade

P. Kosmidis (Athens, Greece)
Webcast
22
Second line therapy for advanced non-small cell lung cancer
Place a comment or grade

M. Cullen (Birmingham, United Kingdom)
Webcast
23
Surgery in selected cases
Place a comment or grade

W. Klepetko (Wien, Austria)
Webcast
24
Will stereotactic body radiotherapy prolong survival in patients with stage IV NSCLC?
Place a comment or grade

P. Baumann (Stockholm, Sweden)
Webcast

Neuroendocrine tumors, mesothelioma and thymoma
25
Small cell lung cancer
Place a comment or grade

J-P. Sculier (Brussels, Belgium)
Webcast
26
Other neuroendocrine tumors
Place a comment or grade

E. Lim (London, United Kingdom)
Webcast
27
Tumors of the thymus
Place a comment or grade

F. Venuta (Rome, Italy)
Webcast

Individualised therapy based on tumor features
28
Challenges and limitations of individualised therapy
Place a comment or grade

M. Taron (Lugano, Switzerland)
Webcast

Elderly and co-morbid patients
29
Radiotherapy
Place a comment or grade

C. Faivre-Finn (Manchester, United Kingdom)
Webcast
30
Systemic treatment
Place a comment or grade

C. Gridelli (Avellino, Italy)
Webcast

European treatment guidelines
31
ESMO clinical recommendations - NSCLC
Place a comment or grade

G. D'Addario (Schaffhausen, Switzerland)
Webcast
32
European treatment guidelines: small cell lung cancer (SCLC)
Place a comment or grade

J. Soerensen (Copenhagen, Denmark)
Webcast
33
European treatment guidelines: mesothelioma
Place a comment or grade

R. Stahel (Zurich, Switzerland)
Webcast

Future developments in multidisciplinary treatments: where are we going?
34
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Place a comment or grade

D. De Ruysscher (Maastricht, The Netherlands)
Webcast
35
NSCLC stage IV
Place a comment or grade

L. Crino (Perugia, Italy)
Webcast

                     
 

WHAT YOU CAN FIND HERE  
Webcast
Webcast

   
 
The EMCTO webcast is supported by an unrestricted educational grant by sanofi aventis.
   
ERS